BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, Starosławska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi GV, Magazzù D, McNally V, Douthwaite H, Ross G, Valagussa P. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 2016;17:791-800. [PMID: 27179402 DOI: 10.1016/S1470-2045(16)00163-7] [Cited by in Crossref: 317] [Cited by in F6Publishing: 144] [Article Influence: 52.8] [Reference Citation Analysis]
Number Citing Articles
1 Shao Y, Yu Y, Luo Z, Guan H, Zhu F, He Y, Chen Q, Liu C, Nie B, Liu H. Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis. Ann Surg Oncol 2022. [PMID: 35933542 DOI: 10.1245/s10434-022-12369-4] [Reference Citation Analysis]
2 Aragón-sánchez S, Ciruelos-gil E, López-marín L, Galindo A, Tabuenca-mateos MJ, Jiménez-arranz S, Colmenero-hernández M, Oliver-pérez MR. Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer. Surgical Oncology 2022. [DOI: 10.1016/j.suronc.2022.101823] [Reference Citation Analysis]
3 Rubovszky G, Kocsis J, Boér K, Chilingirova N, Dank M, Kahán Z, Kaidarova D, Kövér E, Krakovská BV, Máhr K, Mriňáková B, Pikó B, Božović-spasojević I, Horváth Z. Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. Pathol Oncol Res 2022;28:1610383. [DOI: 10.3389/pore.2022.1610383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Tu SM, Singh SR, Arnaoutakis K, Malapati S, Bhatti SA, Joon AY, Atiq OT, Pisters LL. Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench. Cancers (Basel) 2022;14:3345. [PMID: 35884406 DOI: 10.3390/cancers14143345] [Reference Citation Analysis]
5 Pusch R. Neoadjuvant treatment in solid tumors—the earlier, the better in breast cancer. memo. [DOI: 10.1007/s12254-022-00819-4] [Reference Citation Analysis]
6 Ferrando-díez A, Felip E, Pous A, Bergamino Sirven M, Margelí M. Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. Cancers 2022;14:3305. [DOI: 10.3390/cancers14143305] [Reference Citation Analysis]
7 Cai Y, Shao Z, Yu K. Determining the Optimal (Neo)Adjuvant Regimen for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Regarding Survival Outcome: A Network Meta-Analysis. Front Immunol 2022;13:919369. [DOI: 10.3389/fimmu.2022.919369] [Reference Citation Analysis]
8 Hall BJ, Bhojwani AA, Wong H, Law A, Flint H, Ahmed E, Innes H, Cliff J, Malik Z, O’hagan JE, Hall A, Sripadam R, Tolan S, Ali Z, Hart C, Errington D, Alam F, Giuliani R, Mehta S, Khanduri S, Thorp N, Jackson R, Cicconi S, Palmieri C, Mishra A. Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience. The Breast Journal 2022;2022:1-10. [DOI: 10.1155/2022/7146172] [Reference Citation Analysis]
9 Huober J, Barrios CH, Niikura N, Jarząb M, Chang YC, Huggins-Puhalla SL, Pedrini J, Zhukova L, Graupner V, Eiger D, Henschel V, Gochitashvili N, Lambertini C, Restuccia E, Zhang H. Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. J Clin Oncol 2022;:JCO2102772. [PMID: 35763704 DOI: 10.1200/JCO.21.02772] [Reference Citation Analysis]
10 Hong J, Park YH. Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer. Ther Adv Med Oncol 2022;14:17588359221106564. [PMID: 35756967 DOI: 10.1177/17588359221106564] [Reference Citation Analysis]
11 Özdemir Ö, Zengel B, Yildiz Y, Oyan Uluç B, Çabuk D, Özden E, Kivrak Salim D, Paydas S, Demir A, Diker Ö, Nur Pilanci K, Uysal Sönmez Ö, Vatansever S, Doğan İ, Gülmez A, Çakar B, Gürsoy P, Emre Yildirim M, Ayhan M, Karadurmuş N, Bariş Aykan M, Tuğba Çevik G, Şakalar T, Hacibekiroğlu İ, Belen Gülbağci B, Dinçer M, Bayir Garbioğlu D, Kemal Y, Nayir E, Taşkaynatan H, Yilmaz M, Avci O, Sari M, Çoban E, Mustafa Atci M, Aktürk Esen S, Akin Telli T, Karataş F, İnal A, Demir H, Önal Kalkan N, Yilmaz C, Taşli F, Alacacioğlu A. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs 2022. [PMID: 35703239 DOI: 10.1097/CAD.0000000000001310] [Reference Citation Analysis]
12 Irelli A, Parisi A, D'Orazio C, Sidoni T, Rotondaro S, Patruno L, Pavese F, Bafile A, Resta V, Pizzorno L, Ciuffetelli V, Dal Mas A, Calvisi G, Di Sibio A, Marzullo A, Zelli V, Compagnoni C, Tessitore A, Alesse E, Ficorella C, Cortellini A, Cannita K. Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status. Cancers (Basel) 2022;14:3003. [PMID: 35740668 DOI: 10.3390/cancers14123003] [Reference Citation Analysis]
13 Yu J, Li NL. Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report. World J Clin Cases 2022; 10(17): 5923-5928 [DOI: 10.12998/wjcc.v10.i17.5923] [Reference Citation Analysis]
14 Mcgee SF, Clemons M, Savard M. Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective. Current Oncology 2022;29:4125-37. [DOI: 10.3390/curroncol29060329] [Reference Citation Analysis]
15 Spring LM, Bar Y, Isakoff SJ. The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer. J Natl Compr Canc Netw 2022;20:723-34. [PMID: 35714678 DOI: 10.6004/jnccn.2022.7016] [Reference Citation Analysis]
16 Dang C, Ewer MS, Delaloge S, Ferrero JM, Colomer R, de la Cruz-Merino L, Werner TL, Dadswell K, Verrill M, Eiger D, Sarkar S, de Haas SL, Restuccia E, Swain SM. BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. Cancers (Basel) 2022;14:2596. [PMID: 35681574 DOI: 10.3390/cancers14112596] [Reference Citation Analysis]
17 Ma J, Chen W, Hu Z, Huang J, Guo C, Zou C, Yang G. Rare ocular toxicity induced by pertuzumab/QL1209 in healthy chinese subjects: case reports and whole-exome sequencing analysis. Invest New Drugs 2022. [PMID: 35596833 DOI: 10.1007/s10637-022-01256-0] [Reference Citation Analysis]
18 Waks AG, Desai NV, Li T, Poorvu PD, Partridge AH, Sinclair N, Spring LM, Faggen M, Constantine M, Metzger O, Alberti J, Deane J, Rosenberg SM, Frank E, Tolaney SM, Krop IE, Tung NM, Tayob N, King TA, Mittendorf EA, Winer EP. A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. NPJ Breast Cancer 2022;8:63. [PMID: 35538105 DOI: 10.1038/s41523-022-00429-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Xie LY, Wang K, Chen HL, Shi YX, Zhang YQ, Lin HY, Liang YK, Xiao YS, Wu ZY, Yuan ZY, Qiu SQ. Markers Associated With Tumor Recurrence in Patients With Breast Cancer Achieving a Pathologic Complete Response After Neoadjuvant Chemotherapy. Front Oncol 2022;12:860475. [PMID: 35515127 DOI: 10.3389/fonc.2022.860475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Kong H, Wang X, Zhang X. Exercise for Osteoarthritis: A Literature Review of Pathology and Mechanism. Front Aging Neurosci 2022;14:854026. [DOI: 10.3389/fnagi.2022.854026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Agostinetto E, Montemurro F, Puglisi F, Criscitiello C, Bianchini G, Del Mastro L, Introna M, Tondini C, Santoro A, Zambelli A. Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives. Cancers (Basel) 2022;14:2136. [PMID: 35565264 DOI: 10.3390/cancers14092136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Rasti AR, Guimaraes-Young A, Datko F, Borges VF, Aisner DL, Shagisultanova E. PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. JCO Precis Oncol 2022;6:e2100370. [PMID: 35357905 DOI: 10.1200/PO.21.00370] [Reference Citation Analysis]
23 Guarneri V, de Azambuja E. Anthracyclines in the treatment of patients with early breast cancer. ESMO Open 2022. [DOI: 10.1016/j.esmoop.2022.100461] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Le D, Vargo C, Collins S, Williams N, Palettas M, Berger M. Impact of Dose Intensity on Pathologic Complete Response Rate in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab and Pertuzumab (TCHP). Target Oncol 2022. [PMID: 35325355 DOI: 10.1007/s11523-022-00874-1] [Reference Citation Analysis]
25 Ferraro E, Singh J, Patil S, Razavi P, Modi S, Chandarlapaty S, Barrio AV, Malani R, Mellinghoff IK, Boire A, Wen HY, Brogi E, Seidman AD, Norton L, Robson ME, Dang CT. Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. NPJ Breast Cancer 2022;8:37. [PMID: 35319017 DOI: 10.1038/s41523-022-00380-7] [Reference Citation Analysis]
26 Venetis K, Crimini E, Sajjadi E, Corti C, Guerini-rocco E, Viale G, Curigliano G, Criscitiello C, Fusco N. HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. Front Mol Biosci 2022;9:834651. [DOI: 10.3389/fmolb.2022.834651] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Ligorio F, Zambelli L, Fucà G, Lobefaro R, Santamaria M, Zattarin E, de Braud F, Vernieri C. Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications. Ther Adv Med Oncol 2022;14:175883592210791. [DOI: 10.1177/17588359221079123] [Reference Citation Analysis]
28 Guarneri V, Griguolo G, Miglietta F, Conte PF, Dieci MV, Girardi F. Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials. ESMO Open 2022;7:100433. [PMID: 35276440 DOI: 10.1016/j.esmoop.2022.100433] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
29 Magalhães D, Rangel I, Mesquita A. HER2-Positive Inflammatory Breast Cancer Challenges of Clinical Practices. Cureus. [DOI: 10.7759/cureus.22925] [Reference Citation Analysis]
30 Hung C, Tsai I, Hsu C, Lin H. Clinical Outcomes of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 Breast Cancer Patients: A Single-Center Retrospective Study. JCM 2022;11:1434. [DOI: 10.3390/jcm11051434] [Reference Citation Analysis]
31 Li F, Ju Q, Gao C, Li J, Wang X, Yan M, Zhang L, Huang M, Long Q, Jin X, Li N. Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab. Front Oncol 2022;12:819818. [DOI: 10.3389/fonc.2022.819818] [Reference Citation Analysis]
32 McCaffrey RL, Thompson JL, Oudsema RH, Sciallis AP, Cobain EF, Sabel MS, Jeruss JS. Management of early stage HER2 positive breast cancer and increased implementation of axillary imaging to improve identification of nodal metastasis. J Surg Oncol 2022. [PMID: 35230701 DOI: 10.1002/jso.26840] [Reference Citation Analysis]
33 Gandhi S, Brackstone M, Hong NJL, Grenier D, Donovan E, Lu F, Skarpathiotakis M, Lee J, Boileau J, Perera F, Simmons C, Joy AA, Tran WT, Tyono I, Van Massop A, Khalfan S; The Canadian National Neoadjuvant Breast Cancer Consortium. A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles. Breast Cancer Res Treat. [DOI: 10.1007/s10549-022-06522-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Jagiełło-gruszfeld AI, Rosinska M, Meluch M, Pogoda K, Niwinska A, Sienkiewicz R, Grous A, Winter P, Nowecki ZI. Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland. Cancers 2022;14:1218. [DOI: 10.3390/cancers14051218] [Reference Citation Analysis]
35 Lee MX, Wong ALA, Ow S, Sundar R, Tan DSP, Soo RA, Chee CE, Lim JSJ, Yong WP, Lim SE, Goh BC, Wang L, Lee SC. Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors. Target Oncol 2022. [PMID: 35195837 DOI: 10.1007/s11523-022-00867-0] [Reference Citation Analysis]
36 Muraro E, De Zorzi M, Miolo G, Lombardi D, Scalone S, Spazzapan S, Massarut S, Perin T, Dolcetti R, Steffan A, De Re V. KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer. Front Immunol 2021;12:791958. [PMID: 35095867 DOI: 10.3389/fimmu.2021.791958] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Wang J, Wang X, Chen R, Liang M, Li M, Ma G, Xia T, Wang S. Circulating tumor cells may serve as a supplement to RECIST in neoadjuvant chemotherapy of patients with locally advanced breast cancer. Int J Clin Oncol 2022. [PMID: 35122586 DOI: 10.1007/s10147-022-02125-9] [Reference Citation Analysis]
38 Gunasekara ADM, Anothaisintawee T, Youngkong S, Ha NT, Mckay GJ, Attia J, Thakkinstian A. Neoadjuvant Treatment with HER2-Targeted Therapies in HER2-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis. Cancers 2022;14:523. [DOI: 10.3390/cancers14030523] [Reference Citation Analysis]
39 Simmons C, Rayson D, Joy AA, Henning JW, Lemieux J, McArthur H, Card PB, Dent R, Brezden-Masley C. Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines. Ther Adv Med Oncol 2022;14:17588359211066677. [PMID: 35035535 DOI: 10.1177/17588359211066677] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
40 Conte B, Montemurro F, Levaggi A, Blondeaux E, Molinelli C, Cardinali B, Poggio F, Buzzatti G, Bighin C, Lambertini M, Del Mastro L. Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial. Tumori 2022;:3008916211067568. [PMID: 34989265 DOI: 10.1177/03008916211067568] [Reference Citation Analysis]
41 Prakash I, Neely NB, Thomas SM, Sammons S, Blitzblau RC, DiLalla GA, Hyslop T, Menendez CS, Plichta JK, Rosenberger LH, Fayanju OM, Hwang ES, Greenup RA. Utilization of neoadjuvant chemotherapy in high-risk, node-negative early breast cancer. Cancer Med 2022. [PMID: 34989142 DOI: 10.1002/cam4.4517] [Reference Citation Analysis]
42 Ling Y, Liang G, Lin Q, Fang X, Luo Q, Cen Y, Mehrpour M, Hamai A, Liu Z, Shi Y, Li J, Lin W, Jia S, Yang W, Liu Q, Song E, Li J, Gong C. circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer. Mol Cancer 2022;21:8. [PMID: 34980129 DOI: 10.1186/s12943-021-01476-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Mery B, Toussaint P, Heudel PE, Dufresne A, Carbonnaux M, Vanacker H, Bachelot T, Trédan O. Nouvelles stratégies thérapeutiques dans les cancers du sein HER2-surexprimé: New therapeutic strategies in HER2-positive breast cancer. Bull Cancer 2021;108:11S8-11S18. [PMID: 34969516 DOI: 10.1016/S0007-4551(21)00632-9] [Reference Citation Analysis]
44 Latino N, Galotti M, Cherny N, de Vries E, Douillard J, Kaidarova D, Ilbawi A. Prioritising systemic cancer therapies applying ESMO’s tools and other resources to assist in improving cancer care globally: the Kazakh experience. ESMO Open 2022. [DOI: 10.1016/j.esmoop.2021.100362] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Pernas S, Guerriero JL, Naumenko S, Goel S, Regan MM, Hu J, Harrison BT, Lynce F, Lin NU, Partridge A, Morikawa A, Hutchinson J, Mittendorf EA, Sokolov A, Overmoyer B. Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer. Ther Adv Med Oncol 2022;14:175883592211132. [DOI: 10.1177/17588359221113269] [Reference Citation Analysis]
46 Aebi S, Karlsson P, Wapnir IL. Locally advanced breast cancer. Breast 2021:S0960-9776(21)01017-1. [PMID: 34930650 DOI: 10.1016/j.breast.2021.12.011] [Reference Citation Analysis]
47 Alhussein MM, Mokbel A, Cosman T, Aghel N, Yang EH, Mukherjee SD, Dent S, Ellis PM, Dhesy-Thind S, Leong DP. Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis. CJC Open 2021;3:1372-82. [PMID: 34901806 DOI: 10.1016/j.cjco.2021.06.019] [Reference Citation Analysis]
48 Cai JH, Zheng JH, Lin XQ, Lin WX, Zou J, Chen YK, Li ZY, Chen YX. Individualized treatment of breast cancer with chronic renal failure: A case report and review of literature. World J Clin Cases 2021; 9(33): 10345-10354 [PMID: 34904109 DOI: 10.12998/wjcc.v9.i33.10345] [Reference Citation Analysis]
49 Triulzi T, Bianchini G, Di Cosimo S, Pienkowski T, Im YH, Bianchi GV, Galbardi B, Dugo M, De Cecco L, Tseng LM, Liu MC, Bermejo B, Semiglazov V, Viale G, de la Haba-Rodriguez J, Oh DY, Poirier B, Valagussa P, Gianni L, Tagliabue E. The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial. Mol Oncol 2021. [PMID: 34816585 DOI: 10.1002/1878-0261.13141] [Reference Citation Analysis]
50 Kruse ML, Kang IM, Bagegni NA, Howell WT, Moore HCF, Bedell CH, Stokoe CT. Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature. Oncol Ther 2021. [PMID: 34800263 DOI: 10.1007/s40487-021-00178-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Morales S, Gasol A, Sanchez DR. Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments. Cancers (Basel) 2021;13:5771. [PMID: 34830927 DOI: 10.3390/cancers13225771] [Reference Citation Analysis]
52 Chen HL, Chen Q, Deng YC. Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer. Medicine (Baltimore) 2021;100:e27632. [PMID: 34871229 DOI: 10.1097/MD.0000000000027632] [Reference Citation Analysis]
53 Chen D, Kelly C, Haw TJ, Lombard JM, Nordman IIC, Croft AJ, Ngo DTM, Sverdlov AL. Heart Failure in Breast Cancer Survivors: Focus on Early Detection and Novel Biomarkers. Curr Heart Fail Rep 2021;18:362-77. [PMID: 34731413 DOI: 10.1007/s11897-021-00535-w] [Reference Citation Analysis]
54 Zhou D, Wu Y, Jiang K, Xu F, Hong R, Wang S. Identification of a risk prediction model for clinical prognosis in HER2 positive breast cancer patients. Genomics 2021;113:4088-97. [PMID: 34666190 DOI: 10.1016/j.ygeno.2021.10.010] [Reference Citation Analysis]
55 Duranti S, Fabi A, Filetti M, Falcone R, Lombardi P, Daniele G, Franceschini G, Carbognin L, Palazzo A, Garganese G, Paris I, Scambia G, Pietragalla A. Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials. Cancers (Basel) 2021;13:5198. [PMID: 34680350 DOI: 10.3390/cancers13205198] [Reference Citation Analysis]
56 Han YQ, Yi ZB, Yu P, Wang WN, Ouyang QC, Yan M, Wang XJ, Hu XC, Jiang ZF, Huang T, Tong ZS, Wang SS, Yin YM, Li H, Yang RX, Yang HW, Teng YE, Sun T, Cai L, Li HY, Ouyang XN, He JJ, Liu XL, Yang SE, Qiao YL, Fan JH, Wang JY, Xu BH. Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China. J Oncol 2021;2021:6621722. [PMID: 34567118 DOI: 10.1155/2021/6621722] [Reference Citation Analysis]
57 Gidwani R, Franks JA, Enogela EM, Caston NE, Williams CP, Aswani MS, Azuero A, Rocque GB. Survival in the Real World: A National Analysis of Patients Treated for Early-Stage Breast Cancer. JCO Oncol Pract 2021;:OP2100274. [PMID: 34558316 DOI: 10.1200/OP.21.00274] [Reference Citation Analysis]
58 Barbieri MA, Sorbara EE, Cicala G, Santoro V, Cutroneo PM, Franchina T, Spina E. Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database. Drugs Real World Outcomes 2021. [PMID: 34528216 DOI: 10.1007/s40801-021-00278-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Borges A, Pereira F, Redondo P, Antunes L, Vieira C, Antunes P, Bento MJ, Sousa S, Lopes JM, Rocha-Gonçalves F, de Sousa JA, Pereira DS, Borges M. The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data. Health Econ Rev 2021;11:33. [PMID: 34505956 DOI: 10.1186/s13561-021-00332-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Early Breast Cancer Trialists’ Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol 2021;22:1139-50. [PMID: 34339645 DOI: 10.1016/S1470-2045(21)00288-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Song Y, Liu H. A review on the relationship between anti-mullerian hormone and fertility in treating young breast cancer patients. BMC Womens Health 2021;21:295. [PMID: 34376160 DOI: 10.1186/s12905-021-01420-3] [Reference Citation Analysis]
62 Tokunaga E, Masuda N, Yamamoto N, Iwata H, Bando H, Aruga T, Ohtani S, Fujisawa T, Takano T, Inoue K, Suganuma N, Takada M, Aogi K, Sakurai K, Shigematsu H, Kuroi K, Haga H, Ohno S, Morita S, Toi M. Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study). Cancers (Basel) 2021;13:4008. [PMID: 34439165 DOI: 10.3390/cancers13164008] [Reference Citation Analysis]
63 Upton R, Banuelos A, Feng D, Biswas T, Kao K, McKenna K, Willingham S, Ho PY, Rosental B, Tal MC, Raveh T, Volkmer JP, Pegram MD, Weissman IL. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proc Natl Acad Sci U S A 2021;118:e2026849118. [PMID: 34257155 DOI: 10.1073/pnas.2026849118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
64 Liu SN, Lu T, Jin JY, Li C, Girish S, Melnikov F, Badovinac Crnjevic T, Machackova Z, Restuccia E, Kirschbrown WP. Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics. J Clin Pharmacol 2021;61:1096-105. [PMID: 33719071 DOI: 10.1002/jcph.1855] [Reference Citation Analysis]
65 Eiger D, Franzoi MA, Pondé N, Brandão M, de Angelis C, Schmitt Nogueira M, de Hemptinne Q, de Azambuja E. Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials. ESMO Open 2020;5:e000659. [PMID: 32079624 DOI: 10.1136/esmoopen-2019-000659] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
66 Fehm TN, Stickeler E, Fasching PA, Janni W, Kolberg-Liedtke C, Kolberg HC, Lüftner D, Müller V, Schütz F, Thomssen C, Belleville E, Behrens A, Bader S, Untch M, Welslau M, Würstlein R, Thill M, Krug D, Hartkopf AD. Update Breast Cancer 2021 Part 3 - Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. Geburtshilfe Frauenheilkd 2021;81:654-65. [PMID: 34168379 DOI: 10.1055/a-1487-7642] [Reference Citation Analysis]
67 Jagosky M, Tan AR. Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data. Breast Cancer (Dove Med Press) 2021;13:393-407. [PMID: 34163239 DOI: 10.2147/BCTT.S176514] [Reference Citation Analysis]
68 Dempsey N, Rosenthal A, Dabas N, Kropotova Y, Lippman M, Bishopric NH. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat 2021;188:21-36. [PMID: 34115243 DOI: 10.1007/s10549-021-06280-x] [Reference Citation Analysis]
69 Bae SJ, Kim JH, Ahn SG, Jeung HC, Sohn J, Kim GM, Kim MH, Kim SI, Park S, Park HS, Kim JY, Jeong J. Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer. Front Oncol 2021;11:689587. [PMID: 34150658 DOI: 10.3389/fonc.2021.689587] [Reference Citation Analysis]
70 Jeong YH, Hong SA, Ahn HS, Ahn SK, Kim MK. Clinicopathologic factors affecting discrepancies in HER2 overexpression between core needle biopsy and surgical biopsy in breast cancer patients according to neoadjuvant treatment or not. J Cancer 2021;12:4722-8. [PMID: 34149935 DOI: 10.7150/jca.59419] [Reference Citation Analysis]
71 He X, Dai X, Ji J, Liu H, Shi G, Yeung SJ. Nine-Year Median Follow-up of Ccardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients. Clin Breast Cancer 2021:S1526-8209(21)00136-1. [PMID: 34312098 DOI: 10.1016/j.clbc.2021.05.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
72 Martelli V, Latocca MM, Ruelle T, Perachino M, Arecco L, Beshiri K, Razeti MG, Tagliamento M, Cosso M, Fregatti P, Lambertini M. Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women. Breast Cancer (Dove Med Press) 2021;13:341-51. [PMID: 34079366 DOI: 10.2147/BCTT.S274283] [Reference Citation Analysis]
73 Okines AFC, Kipps E, Irfan T, Coakley M, Angelis V, Asare B, Mohammed K, Walsh G, Ring A, Johnston SRD, Parton M, Turner NC, Smith IE. Impact of timing of adjuvant chemothapy for early breast cancer: the Royal Marsden Hospital experience. Br J Cancer 2021;125:299-304. [PMID: 34017085 DOI: 10.1038/s41416-021-01428-4] [Reference Citation Analysis]
74 Boér K, Kahán Z, Landherr L, Csőszi T, Máhr K, Ruzsa Á, Horváth Z, Budai B, Rubovszky G. Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer - Increasing Rates of Breast Conserving Surgery: A Real-World Experience. Pathol Oncol Res 2021;27:1609785. [PMID: 34257621 DOI: 10.3389/pore.2021.1609785] [Reference Citation Analysis]
75 Groen EJ, van der Noordaa MEM, Schaapveld M, Sonke GS, Mann RM, van Ramshorst MS, Lips EH, Vrancken Peeters MTFD, van Duijnhoven FH, Wesseling J. Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer. Breast Cancer Res Treat 2021;189:213-24. [PMID: 33945043 DOI: 10.1007/s10549-021-06235-2] [Reference Citation Analysis]
76 He Q, Li JY, Ren QL. Efficacy of Neoadjuvant Single or Dual Anti-HER-2 Therapy Combined with Chemotherapy in Patients with HER-2-Positive Breast Cancer: A Single-Center Retrospective Study. Asian Pac J Cancer Prev 2021;22:1467-75. [PMID: 34048175 DOI: 10.31557/APJCP.2021.22.5.1467] [Reference Citation Analysis]
77 Ligorio F, Zambelli L, Bottiglieri A, Castagnoli L, Zattarin E, Lobefaro R, Ottini A, Vingiani A, Pupa SM, Bianchi GV, Capri G, Pruneri G, de Braud F, Vernieri C. Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients. Ther Adv Med Oncol 2021;13:17588359211006960. [PMID: 33948122 DOI: 10.1177/17588359211006960] [Reference Citation Analysis]
78 Futamura M, Oba M, Masuda N, Bando H, Okada M, Yamamoto Y, Kin T, Saeki T, Nagashima T, Kuwayama T, Toh U, Hirano A, Inokuchi M, Yamagami K, Mizuno Y, Kojima Y, Nakayama T, Yasojima H, Ohno S. Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study). Breast Cancer 2021;28:1023-37. [PMID: 33811599 DOI: 10.1007/s12282-021-01238-9] [Reference Citation Analysis]
79 Zhang J, Yu Y, Lin Y, Kang S, Lv X, Liu Y, Lin J, Wang J, Song C. Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis. Ther Adv Med Oncol 2021;13:17588359211006948. [PMID: 33868462 DOI: 10.1177/17588359211006948] [Reference Citation Analysis]
80 Bešlija S, Gojković Z, Cerić T, Mekić Abazović A, Marijanović I, Vranić S, Mustedanagić-Mujanović J, Skenderi F, Rakita I, Guzijan A, Koprić D, Humačkić A, Trokić D, Alidžanović J, Efendić A, Šišić I, Drljević H, Bešlagić V, Babić B, Pašić A, Ramić A, Mikić D, Guzin Z, Karan D, Buhovac T, Miletić D, Šečić S, Đozić Šahmić A, Mujbegović L, Kubura A, Burina M, Lalović N, Dukić N, Vladičić Mašić J, Ćuk M, Stanušić R. 2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina. Bosn J Basic Med Sci 2021;21:120-35. [PMID: 32415816 DOI: 10.17305/bjbms.2020.4846] [Reference Citation Analysis]
81 Ben Dhia S, Loap P, Loirat D, Vincent-Salomon A, Cao K, Escalup L, Fourquet A, Kirova Y. [Concurrent radiation therapy and dual HER2 blockade in breast cancer: Assessment of toxicity]. Cancer Radiother 2021;25:424-31. [PMID: 33771453 DOI: 10.1016/j.canrad.2020.06.037] [Reference Citation Analysis]
82 Jing S, Zhang A, Chen Y, Shen C, Currin-McCulloch J, Zhu C. Mindfulness-based interventions for breast cancer patients in China across outcome domains: a systematic review and meta-analysis of the Chinese literature. Support Care Cancer 2021;29:5611-21. [PMID: 33770259 DOI: 10.1007/s00520-021-06166-0] [Reference Citation Analysis]
83 Schick J, Ritchie RP, Restini C. Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. Breast Cancer (Auckl) 2021;15:1178223421995854. [PMID: 33994789 DOI: 10.1177/1178223421995854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 Tarantino P, Morganti S, Curigliano G. Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. Exploration of Targeted Anti-tumor Therapy. [DOI: 10.37349/etat.2021.00037] [Reference Citation Analysis]
85 Stoen E, Kagihara J, Shagisultanova E, Fisher CM, Nicklawsky A, Kabos P, Borges VF, Diamond JR. Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval. Breast Cancer Res Treat 2021;187:883-91. [PMID: 33625615 DOI: 10.1007/s10549-021-06132-8] [Reference Citation Analysis]
86 Ito M, Horimoto Y, Sasaki R, Miyazaki S, Orihata G, Saito M. Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases. Case Rep Oncol 2021;14:62-6. [PMID: 33776683 DOI: 10.1159/000513002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Wang W, Guo B, Cui C, Sun T, Liu S. Management of early-stage breast cancer patients during the coronavirus disease 2019 (COVID-19) pandemic: The experience in China from a surgical standpoint. J Cancer 2021;12:2190-8. [PMID: 33758597 DOI: 10.7150/jca.50501] [Reference Citation Analysis]
88 Rocca A, Cortesi P, Cortesi L, Gianni L, Matteucci F, Fantini L, Maestri A, Giunchi DC, Cavanna L, Ciani R, Falcini F, Bagni A, Meldoli E, Dall'Agata M, Volpi R, Andreis D, Nanni O, Curcio A, Lucchi L, Amadori D, Fedeli A. Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer. Ther Adv Med Oncol 2021;13:1758835920985632. [PMID: 33613693 DOI: 10.1177/1758835920985632] [Reference Citation Analysis]
89 Zhang L, Jiang X, Xie X, Wu Y, Zheng S, Tian W, Xie X, Li L. The Impact of Preoperative Radiomics Signature on the Survival of Breast Cancer Patients With Residual Tumors After NAC. Front Oncol 2020;10:523327. [PMID: 33614472 DOI: 10.3389/fonc.2020.523327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, Khan SA, Loibl S, Morris EA, Perez A, Regan MM, Spears PA, Sudheendra PK, Symmans WF, Yung RL, Harvey BE, Hershman DL. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol 2021;39:1485-505. [PMID: 33507815 DOI: 10.1200/JCO.20.03399] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 26.0] [Reference Citation Analysis]
91 Laas E, Bresset A, Féron JG, Le Gal C, Darrigues L, Coussy F, Grandal B, Laot L, Pierga JY, Reyal F, Hamy AS. HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens. Cancers (Basel) 2021;13:370. [PMID: 33498405 DOI: 10.3390/cancers13030370] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Soares ICS, Bello MA, Bergmann A, Thuler LCS. Comparison of the performance of four staging systems in determining the prognosis of breast cancer among women undergoing neoadjuvant chemotherapy. Breast Cancer Res Treat 2021;187:547-55. [PMID: 33417086 DOI: 10.1007/s10549-020-06077-4] [Reference Citation Analysis]
93 Song D, Man X, Jin M, Li Q, Wang H, Du Y. A Decision-Making Supporting Prediction Method for Breast Cancer Neoadjuvant Chemotherapy. Front Oncol 2020;10:592556. [PMID: 33469514 DOI: 10.3389/fonc.2020.592556] [Reference Citation Analysis]
94 Reyes R, Reguart N. Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer. Transl Lung Cancer Res 2021;10:607-21. [PMID: 33569340 DOI: 10.21037/tlcr-20-780] [Reference Citation Analysis]
95 Asaoka M, Gandhi S, Ishikawa T, Takabe K. Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future. Breast Cancer (Auckl) 2020;14:1178223420980377. [PMID: 33402827 DOI: 10.1177/1178223420980377] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
96 Blaes AH, Dang C. Trastuzumab: Weighing the Benefits and the Risks. J Natl Cancer Inst 2020;112:1181-2. [PMID: 32343773 DOI: 10.1093/jnci/djaa055] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
97 Guan J, Zhang M. Cardiotoxicity of anthracycline-free targeted oncological therapies in HER2-positive breast cancer. Oncol Lett 2021;21:100. [PMID: 33376533 DOI: 10.3892/ol.2020.12361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Mano MS. Pathologic response at the epicenter of the treatment decision-making process in Human Epidermal Receptor-Type 2 overexpressing (Her2+) Early Breast Cancer (EBC): Challenges and opportunities for financially-constrained healthcare systems. Breast 2020;54:331-4. [PMID: 33279792 DOI: 10.1016/j.breast.2020.11.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
99 Fiste O, Liontos M, Koutsoukos K, Terpos E, Dimopoulos MA, Zagouri F. Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review. Ann Transl Med 2020;8:1603. [PMID: 33437802 DOI: 10.21037/atm-20-1175] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
100 Weinberg F, Peckys DB, de Jonge N. EGFR Expression in HER2-Driven Breast Cancer Cells. Int J Mol Sci 2020;21:E9008. [PMID: 33260837 DOI: 10.3390/ijms21239008] [Reference Citation Analysis]
101 Boudy AS, Ferrier C, Selleret L, Zilberman S, Arfi A, Sussfeld J, Gligorov J, Richard S, Bendifallah S, Chabbert-Buffet N, Touboul C, Daraï E. Prognosis of HER2-positive pregnancy-associated breast cancer: Analysis from the French CALG (Cancer Associé à La Grossesse) network. Breast 2020;54:311-8. [PMID: 33271423 DOI: 10.1016/j.breast.2020.11.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
102 Roy PG, Verhoeven D. Neoadjuvant dual anti-HER2 therapy for early breast cancer: where do we stand? Gland Surg 2020;9:1167-9. [PMID: 33224790 DOI: 10.21037/gs.2020.03.12] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Baker JL, Hegde J, Thompson CK, Lee MK, Dinome ML. Locoregional Management of Inflammatory Breast Cancer. Curr Breast Cancer Rep 2020;12:326-35. [DOI: 10.1007/s12609-020-00389-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
104 Ha R, Chin C, Karcich J, Liu MZ, Chang P, Mutasa S, Pascual Van Sant E, Wynn RT, Connolly E, Jambawalikar S. Prior to Initiation of Chemotherapy, Can We Predict Breast Tumor Response? Deep Learning Convolutional Neural Networks Approach Using a Breast MRI Tumor Dataset. J Digit Imaging. 2019;32:693-701. [PMID: 30361936 DOI: 10.1007/s10278-018-0144-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
105 Laakmann E, Emons J, Taran FA, Janni W, Uhrig S, Overkamp F, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Schulmeyer C, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Volz B, Fasching PA, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Hartkopf AD. Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. Geburtshilfe Frauenheilkd 2020;80:1134-42. [PMID: 33173241 DOI: 10.1055/a-1286-2917] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
106 Huebner H, Kurbacher CM, Kuesters G, Hartkopf AD, Lux MP, Huober J, Volz B, Taran FA, Overkamp F, Tesch H, Häberle L, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Ruebner M, Untch M, Fasching PA, Janni W, Fehm TN, Kolberg HC, Wallwiener D, Brucker SY, Schneeweiss A, Ettl J. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. BMC Cancer 2020;20:1091. [PMID: 33176725 DOI: 10.1186/s12885-020-07546-1] [Reference Citation Analysis]
107 Allison KH. Prognostic and predictive parameters in breast pathology: a pathologist's primer. Mod Pathol 2021;34:94-106. [PMID: 33154551 DOI: 10.1038/s41379-020-00704-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
108 Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Du FL, Dupré PF, Bachelot T, Gabelle P, Chauvet MP, Coeffic D, Barbe C, Prevost JB, Paintaud G, Thibault G, Ferhat A, Dupin J, Berriolo-Riedinger A, Arnould L. Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study. EClinicalMedicine 2020;28:100566. [PMID: 33205032 DOI: 10.1016/j.eclinm.2020.100566] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
109 Ban M, Petrić Miše B, Vrdoljak E. Early HER2-Positive Breast Cancer: Current Treatment and Novel Approaches. Breast Care (Basel) 2020;15:560-9. [PMID: 33447229 DOI: 10.1159/000511883] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
110 Lu J, Wu Z, Peng J, Xu S, Zhou L, Lin Y, Wang Y, Yin W, Lu J. Programmed death-ligand 1 single nucleotide polymorphism affects breast cancer chemosensitivity and adverse events in the neoadjuvant setting. Int J Biol Markers 2020;35:90-101. [PMID: 33073683 DOI: 10.1177/1724600820926172] [Reference Citation Analysis]
111 Michel LL, Hartkopf AD, Fasching PA, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Volz B, Huebner H, Wimberger P, Hielscher C, Mundhenke C, Kurbacher C, Wuerstlein R, Untch M, Overkamp F, Huober J, Janni W, Taran FA, Lux MP, Wallwiener D, Brucker SY, Schneeweiss A, Fehm TN. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. Cancers (Basel) 2020;12:E3021. [PMID: 33080911 DOI: 10.3390/cancers12103021] [Reference Citation Analysis]
112 Simionescu AA, Horobeț A, Belaşcu L, Median DM. Real-World Data Analysis of Pregnancy-Associated Breast Cancer at a Tertiary-Level Hospital in Romania. Medicina (Kaunas) 2020;56:E522. [PMID: 33036248 DOI: 10.3390/medicina56100522] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Wang C, Chen J, Xu X, Hu X, Kong D, Liang G, Wang X. Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review. Technol Cancer Res Treat 2020;19:1533033820960721. [PMID: 32990165 DOI: 10.1177/1533033820960721] [Reference Citation Analysis]
114 BeLow M, Osipo C. Notch Signaling in Breast Cancer: A Role in Drug Resistance. Cells 2020;9:E2204. [PMID: 33003540 DOI: 10.3390/cells9102204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
115 Trimboli RM, Giorgi Rossi P, Battisti NML, Cozzi A, Magni V, Zanardo M, Sardanelli F. Do we still need breast cancer screening in the era of targeted therapies and precision medicine? Insights Imaging 2020;11:105. [PMID: 32975658 DOI: 10.1186/s13244-020-00905-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
116 Yamashita S, Hattori N, Fujii S, Yamaguchi T, Takahashi M, Hozumi Y, Kogawa T, El-Omar O, Liu YY, Arai N, Mori A, Higashimoto H, Ushijima T, Mukai H. Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy. Sci Rep 2020;10:15530. [PMID: 32968149 DOI: 10.1038/s41598-020-72661-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
117 Earl H, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Rea D, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mahler-Araujo B, Provenzano E, Chhabra A, Gasson S, Balmer C, Abraham JE, Caldas C, Hall P, Shinkins B, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. Health Technol Assess 2020;24:1-190. [PMID: 32880572 DOI: 10.3310/hta24400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
118 Liu MZ, Mutasa S, Chang P, Siddique M, Jambawalikar S, Ha R. A novel CNN algorithm for pathological complete response prediction using an I-SPY TRIAL breast MRI database. Magn Reson Imaging 2020;73:148-51. [PMID: 32889091 DOI: 10.1016/j.mri.2020.08.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
119 Chainitikun S, Saleem S, Lim B, Valero V, Ueno NT. Update on systemic treatment for newly diagnosed inflammatory breast cancer. J Adv Res 2021;29:1-12. [PMID: 33842000 DOI: 10.1016/j.jare.2020.08.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Wege AK, Kirchhammer N, Kazandjian LV, Prassl S, Brandt M, Piendl G, Ortmann O, Fischer S, Brockhoff G. A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM). J Transl Med 2020;18:316. [PMID: 32799890 DOI: 10.1186/s12967-020-02484-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
121 Dediu M, Zielinski C. Reply to the Correspondence by Untch et al. "Concerning Dediu M, Zielinski C: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer" [Breast Care 2019; DOI 10.1159/000500624]. Breast Care (Basel) 2020;15:314-6. [PMID: 32774227 DOI: 10.1159/000502508] [Reference Citation Analysis]
122 S Mano M. Trastuzumab emtansine: a game changer in HER2-positive early breast cancer. Future Oncol 2020;16:2595-609. [PMID: 32734779 DOI: 10.2217/fon-2020-0219] [Reference Citation Analysis]
123 Patel A, Unni N, Peng Y. The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer. Cancers (Basel) 2020;12:E2081. [PMID: 32731409 DOI: 10.3390/cancers12082081] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
124 Wang C, Lin Y, Zhou Y, Mao F, Zhu H, Guan J, Zhang X, Shen S, Huang X, Chen C, Yao R, Zhao J, Sun Q. Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial. BMC Cancer 2020;20:653. [PMID: 32660609 DOI: 10.1186/s12885-020-07143-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
125 Spring LM, Specht MC, Jimenez RB, Isakoff SJ, Wang GX, Ly A, Shin JA, Bardia A, Moy B. Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic. N Engl J Med 2020;383:262-72. [PMID: 32610007 DOI: 10.1056/NEJMcpc2002422] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
126 Xu B, Li W, Zhang Q, Shao Z, Li Q, Wang X, Li H, Sun T, Yin Y, Zheng H, Feng J, Zhang H, Lei G, Restuccia E. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study. Breast Cancer Res Treat 2020;182:689-97. [PMID: 32564260 DOI: 10.1007/s10549-020-05728-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
127 Pestana RC, Sen S, Hobbs BP, Hong DS. Histology-agnostic drug development - considering issues beyond the tissue. Nat Rev Clin Oncol 2020;17:555-68. [PMID: 32528101 DOI: 10.1038/s41571-020-0384-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
128 Omarini C, Bettelli S, Manfredini S, Barbolini M, Isca C, Cortesi G, Maiorana A, Tazzioli G, Dominici M, Piacentini F. Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy. Transl Oncol 2020;13:100794. [PMID: 32485588 DOI: 10.1016/j.tranon.2020.100794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
129 Cobert AM, Helms C, Larck C, Moore DC. Risk of hepatotoxicity with trastuzumab emtansine in breast cancer patients: a systematic review and meta-analysis. Ther Adv Drug Saf 2020;11:2042098620915058. [PMID: 32341779 DOI: 10.1177/2042098620915058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
130 Vagia E, Mahalingam D, Cristofanilli M. The Landscape of Targeted Therapies in TNBC. Cancers (Basel) 2020;12:E916. [PMID: 32276534 DOI: 10.3390/cancers12040916] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 21.0] [Reference Citation Analysis]
131 Ueno T, Masuda N, Sato N, Ohtani S, Yamamura J, Matsunami N, Kashiwaba M, Takano T, Takahashi M, Kaneko K, Ohno S, Morita S, Toi M. Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study. Jpn J Clin Oncol 2020;50:3-11. [PMID: 31821506 DOI: 10.1093/jjco/hyz119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
132 Yu L, Fu F, Li J, Huang M, Zeng B, Lin Y, Mei Q, Lv J, Wang C. Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Oncol 2020;2020:5169278. [PMID: 32256583 DOI: 10.1155/2020/5169278] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
133 Shao Z, Pang D, Yang H, Li W, Wang S, Cui S, Liao N, Wang Y, Wang C, Chang YC, Wang H, Kang SY, Seo JH, Shen K, Laohawiriyakamol S, Jiang Z, Li J, Zhou J, Althaus B, Mao Y, Eng-Wong J. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial. JAMA Oncol 2020;6:e193692. [PMID: 31647503 DOI: 10.1001/jamaoncol.2019.3692] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
134 Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, Del Mastro L, Ignatiadis M, Pritchard K, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Barrios CH, Baselga J, Moreno-Aspitia A, Piccart M, Gelber RD, de Azambuja E. Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. J Natl Cancer Inst 2019;111:86-94. [PMID: 29878225 DOI: 10.1093/jnci/djy094] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 19.5] [Reference Citation Analysis]
135 Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. J Thorac Oncol 2020;15:709-40. [PMID: 32004713 DOI: 10.1016/j.jtho.2020.01.005] [Cited by in Crossref: 40] [Cited by in F6Publishing: 53] [Article Influence: 20.0] [Reference Citation Analysis]
136 Lei C, Yang C, Xia B, Ji F, Zhang Y, Gao H, Xiong Q, Lin Y, Zhuang X, Zhang L, Zhu T, Cheng M, Yang M, Wang K. Analysis of Tau Protein Expression in Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Different Molecular Subtypes of Breast Cancer. J Breast Cancer 2020;23:47-58. [PMID: 32140269 DOI: 10.4048/jbc.2020.23.e11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
137 Fayanju OM, Ren Y, Greenup RA, Plichta JK, Rosenberger LH, Force J, Suneja G, Devi GR, King TA, Nakhlis F, Hyslop T, Hwang ES. Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients. Breast Cancer Res Treat 2020;180:207-17. [PMID: 31960171 DOI: 10.1007/s10549-020-05529-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
138 Wu J, Kong R, Tian S, Li H, Wu K, Kong L. Can trastuzumab emtansine be replaced by additional chemotherapy plus targeted therapy for HER2-overexpressing breast cancer patients with residual disease after neoadjuvant chemotherapy? Chin J Cancer Res 2019;31:878-91. [PMID: 31949390 DOI: 10.21147/j.issn.1000-9604.2019.06.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
139 Sardesai S, Badawi M, Mrozek E, Morgan E, Phelps M, Stephens J, Wei L, Kassem M, Ling Y, Lustberg M, Stover D, Williams N, Layman R, Reinbolt R, VanDeusen J, Cherian M, Grever M, Carson W, Ramaswamy B, Wesolowski R. A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer. Invest New Drugs 2020;38:1400-10. [PMID: 31953695 DOI: 10.1007/s10637-020-00895-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
140 Batoo S, Bayraktar S, Al-Hattab E, Basu S, Okuno S, Glück S. Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer. J Carcinog 2019;18:5. [PMID: 31949426 DOI: 10.4103/jcar.JCar_14_19] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
141 Tsao LC, Crosby EJ, Trotter TN, Agarwal P, Hwang BJ, Acharya C, Shuptrine CW, Wang T, Wei J, Yang X, Lei G, Liu CX, Rabiola CA, Chodosh LA, Muller WJ, Lyerly HK, Hartman ZC. CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. JCI Insight 2019;4:131882. [PMID: 31689243 DOI: 10.1172/jci.insight.131882] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
142 Montagna E, Colleoni M. Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer. Ther Adv Med Oncol 2019;11:1758835919894105. [PMID: 31897091 DOI: 10.1177/1758835919894105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
143 Lo Gullo R, Eskreis-Winkler S, Morris EA, Pinker K. Machine learning with multiparametric magnetic resonance imaging of the breast for early prediction of response to neoadjuvant chemotherapy. Breast 2020;49:115-22. [PMID: 31786416 DOI: 10.1016/j.breast.2019.11.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
144 Vasmatzis G, Liu MC, Reganti S, Feathers RW, Smadbeck J, Johnson SH, Schaefer Klein JL, Harris FR, Yang L, Kosari F, Murphy SJ, Borad MJ, Thompson EA, Cheville JC, Anastasiadis PZ. Integration of Comprehensive Genomic Analysis and Functional Screening of Affected Molecular Pathways to Inform Cancer Therapy. Mayo Clin Proc 2020;95:306-18. [PMID: 31685261 DOI: 10.1016/j.mayocp.2019.07.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
145 Ishii K, Morii N, Yamashiro H. Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy. Core Evid 2019;14:51-70. [PMID: 31802990 DOI: 10.2147/CE.S217848] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
146 Fayanju OM, Ren Y, Suneja G, Thomas SM, Greenup RA, Plichta JK, Rosenberger LH, Force J, Hyslop T, Hwang ES. Nodal Response to Neoadjuvant Chemotherapy Predicts Receipt of Radiation Therapy After Breast Cancer Diagnosis. Int J Radiat Oncol Biol Phys 2020;106:377-89. [PMID: 31678225 DOI: 10.1016/j.ijrobp.2019.10.039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
147 Alfasi A, Ben-Aharon I. Breast Cancer during Pregnancy-Current Paradigms, Paths to Explore. Cancers (Basel) 2019;11:E1669. [PMID: 31661803 DOI: 10.3390/cancers11111669] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
148 Hardy-Werbin M, Quiroga V, Cirauqui B, Romeo M, Felip E, Teruel I, Garcia JJ, Erasun C, España S, Cucurull M, Montprade E, Pardo JC, Carballo D, Velarde JM, Margeli M. Real-world data on T-DM1 efficacy - results of a single-center retrospective study of HER2-positive breast cancer patients. Sci Rep 2019;9:12760. [PMID: 31484985 DOI: 10.1038/s41598-019-49251-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
149 Abraham J, Montero AJ, Jankowitz RC, Salkeni MA, Beumer JH, Kiesel BF, Piette F, Adamson LM, Nagy RJ, Lanman RB, Sperinde J, Huang W, Allegra CJ, Srinivasan A, Wang Y, Pogue-Geile KL, Lucas PC, Jacobs SA. Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10. J Clin Oncol 2019;37:2601-9. [PMID: 31442103 DOI: 10.1200/JCO.19.00858] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
150 Fayanju OM, Ren Y, Thomas SM, Greenup RA, Plichta JK, Rosenberger LH, Tamirisa N, Force J, Boughey JC, Hyslop T, Hwang ES. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB). Ann Surg 2018;268:591-601. [PMID: 30048319 DOI: 10.1097/SLA.0000000000002953] [Cited by in Crossref: 57] [Cited by in F6Publishing: 23] [Article Influence: 19.0] [Reference Citation Analysis]
151 Rosenbluth JM, Overmoyer BA. Inflammatory Breast Cancer: a Separate Entity. Curr Oncol Rep 2019;21:86. [PMID: 31414257 DOI: 10.1007/s11912-019-0842-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
152 Ditsch N, Untch M, Thill M, Müller V, Janni W, Albert US, Bauerfeind I, Blohmer J, Budach W, Dall P, Diel I, Fasching PA, Fehm T, Friedrich M, Gerber B, Hanf V, Harbeck N, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Möbus V, Müller-Schimpfle M, Mundhenke C, Nitz U, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Wenz F, Witzel I, Wöckel A. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care (Basel) 2019;14:224-45. [PMID: 31558897 DOI: 10.1159/000501000] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 12.7] [Reference Citation Analysis]
153 Palomeras S, Diaz-Lagares Á, Viñas G, Setien F, Ferreira HJ, Oliveras G, Crujeiras AB, Hernández A, Lum DH, Welm AL, Esteller M, Puig T. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer. Breast Cancer Res 2019;21:79. [PMID: 31277676 DOI: 10.1186/s13058-019-1160-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
154 Dent S, Melloni C, Ivars J, Sammons S, Kimmick G. Cardiotoxicities of Modern Treatments in Breast Cancer. Curr Treat Options Cardiovasc Med 2019;21:34. [PMID: 31203459 DOI: 10.1007/s11936-019-0738-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
155 Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Harnett AN, Ah-See ML, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mansi J, Gounaris I, Mahler-Araujo B, Provenzano E, Chhabra A, Abraham JE, Caldas C, Hall PS, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA; PERSEPHONE Steering Committee and Trial Investigators. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet. 2019;393:2599-2612. [PMID: 31178152 DOI: 10.1016/s0140-6736(19)30650-6] [Cited by in Crossref: 91] [Cited by in F6Publishing: 51] [Article Influence: 30.3] [Reference Citation Analysis]
156 Devi GR, Hough H, Barrett N, Cristofanilli M, Overmoyer B, Spector N, Ueno NT, Woodward W, Kirkpatrick J, Vincent B, Williams KP, Finley C, Duff B, Worthy V, McCall S, Hollister BA, Palmer G, Force J, Westbrook K, Fayanju O, Suneja G, Dent SF, Hwang ES, Patierno SR, Marcom PK. Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium. J Cancer 2019;10:3344-51. [PMID: 31293637 DOI: 10.7150/jca.31176] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
157 Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Fasching PA, Afenjar K, Spera G, Lopez-Valverde V, Song C, Trask P, Boulet T, Sparano JA, Symmans WF, Thompson AM, Slamon D. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. J Clin Oncol. 2019;37:2206-2216. [PMID: 31157583 DOI: 10.1200/jco.19.00882] [Cited by in Crossref: 47] [Cited by in F6Publishing: 23] [Article Influence: 15.7] [Reference Citation Analysis]
158 Krystel-Whittemore M, Xu J, Brogi E, Ventura K, Patil S, Ross DS, Dang C, Robson M, Norton L, Morrow M, Wen HY. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Breast Cancer Res Treat 2019;177:61-6. [PMID: 31144151 DOI: 10.1007/s10549-019-05295-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
159 Dediu M, Zielinski C. A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer. Breast Care 2020;15:67-71. [DOI: 10.1159/000500620] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
160 Hariharan N, Rao TS, Rajappa S, Naidu CCK, Raju KVVN, Koppula V, Murthy S, Kodandapani S. Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast - CRBr) - Trial design and conduct. Int J Surg Protoc 2019;16:5-8. [PMID: 31897442 DOI: 10.1016/j.isjp.2019.05.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
161 Lee Chuy K, Yu AF. Cardiotoxicity of Contemporary Breast Cancer Treatments. Curr Treat Options Oncol 2019;20:51. [PMID: 31073788 DOI: 10.1007/s11864-019-0646-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
162 Sabatier R, Charafe-Jauffret E, Pierga JY, Curé H, Lambaudie E, Genre D, Houvenaeghel G, Viens P, Ginestier C, Bertucci F, Sfumato P, Extra JM, Gonçalves A. Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer. J Clin Med 2019;8:E612. [PMID: 31064127 DOI: 10.3390/jcm8050612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
163 Zhang H, Xie P, Li Z, Huang R, Feng W, Kong Y, Xu F, Zhao L, Song Q, Li J, Zhang B, Fan J, Qiao Y, Xie X, Zheng S, He J, Wang K. A nomogram for predicting the HER2 status in female patients with breast cancer in China: a nationwide, multicenter, 10-year epidemiological study. Diagn Pathol 2019;14:35. [PMID: 31054583 DOI: 10.1186/s13000-019-0806-4] [Reference Citation Analysis]
164 Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Kiermaier A, Eng-Wong J, Dang C; BERENICE Study Group. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol 2018;29:646-53. [PMID: 29253081 DOI: 10.1093/annonc/mdx773] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 17.0] [Reference Citation Analysis]
165 Kennedy SP, Han JZR, Portman N, Nobis M, Hastings JF, Murphy KJ, Latham SL, Cadell AL, Miladinovic D, Marriott GR, O'Donnell YEI, Shearer RF, Williams JT, Munoz AG, Cox TR, Watkins DN, Saunders DN, Timpson P, Lim E, Kolch W, Croucher DR. Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer. Breast Cancer Res 2019;21:43. [PMID: 30898150 DOI: 10.1186/s13058-019-1127-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
166 Wu D, Chen T, Jiang H, Duan C, Zhang X, Lin Y, Chen S, Wu F. Comparative Efficacy and Tolerability of Neoadjuvant Immunotherapy Regimens for Patients with HER2-Positive Breast Cancer: A Network Meta-Analysis. J Oncol 2019;2019:3406972. [PMID: 31015833 DOI: 10.1155/2019/3406972] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
167 Wu Z, Zhang L, Peng J, Xu S, Zhou L, Lin Y, Wang Y, Lu J, Yin W, Lu J. Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting. Cancer Biol Ther 2019;20:941-7. [PMID: 30866717 DOI: 10.1080/15384047.2019.1583533] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
168 Watanuki R, Hayashida T, Kawai Y, Kikuchi M, Nakashoji A, Yokoe T, Toyota T, Seki T, Takahashi M, Kitagawa Y. Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients. Int J Clin Oncol 2019;24:807-14. [PMID: 30810890 DOI: 10.1007/s10147-019-01420-2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
169 Caparica R, Lambertini M, Pondé N, Fumagalli D, de Azambuja E, Piccart M. Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives. Ther Adv Med Oncol 2019;11:1758835919827714. [PMID: 30833989 DOI: 10.1177/1758835919827714] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
170 Selli C, Sims AH. Neoadjuvant Therapy for Breast Cancer as a Model for Translational Research. Breast Cancer (Auckl) 2019;13:1178223419829072. [PMID: 30814840 DOI: 10.1177/1178223419829072] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
171 Colomer R, Saura C, Sánchez-Rovira P, Pascual T, Rubio IT, Burgués O, Marcos L, Rodríguez CA, Martín M, Lluch A. Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. Oncologist 2019;24:603-11. [PMID: 30710068 DOI: 10.1634/theoncologist.2018-0228] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
172 Antolín S, Acea B, Albaina L, Concha Á, Santiago P, García-Caballero T, Mosquera JJ, Varela JR, Soler R, Calvo L. Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution. Breast Cancer (Dove Med Press) 2019;11:29-42. [PMID: 30643452 DOI: 10.2147/BCTT.S179750] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
173 Kirschbrown WP, Wynne C, Kågedal M, Wada R, Li H, Wang B, Nijem I, Badovinac Crnjevic T, Gasser H, Heeson S, Eng-Wong J, Garg A. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study. J Clin Pharmacol 2019;59:702-16. [PMID: 30570763 DOI: 10.1002/jcph.1362] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
174 Brzezinska M, Dixon JM. Inflammatory breast cancer: no longer an absolute contraindication for breast conservation surgery following good response to neoadjuvant therapy. Gland Surg 2018;7:520-4. [DOI: 10.21037/gs.2018.08.04] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
175 Wong NS. Primary medical therapy and breast conservation treatment: the medical oncology perspective. Gland Surg 2018;7:560-75. [PMID: 30687629 DOI: 10.21037/gs.2018.10.02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
176 Wöckel A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Hadji P, Tesch H, Ettl J, Lüftner D, Müller V, Welslau M, Belleville E, Brucker SY, Schütz F, Fasching PA, Fehm TN, Schneeweiss A, Kolberg HC. Update Breast Cancer 2018 (Part 3) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer. Geburtshilfe Frauenheilkd 2018;78:1110-8. [PMID: 30498278 DOI: 10.1055/a-0715-2821] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
177 Mollen EWJ, Ient J, Tjan-Heijnen VCG, Boersma LJ, Miele L, Smidt ML, Vooijs MAGG. Moving Breast Cancer Therapy up a Notch. Front Oncol 2018;8:518. [PMID: 30515368 DOI: 10.3389/fonc.2018.00518] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
178 Escrivá-de-Romaní S, Arumí M, Zamora E, Bellet M. Neoadjuvant Model as a Platform for Research in Breast Cancer and Novel Targets under Development in this Field. Breast Care (Basel) 2018;13:251-62. [PMID: 30319327 DOI: 10.1159/000492122] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
179 Guerin M, Gonçalves A, Toiron Y, Baudelet E, Pophillat M, Granjeaud S, Fourquet P, Jacot W, Tarpin C, Sabatier R, Agavnian E, Finetti P, Adelaide J, Birnbaum D, Ginestier C, Charafe-Jauffret E, Viens P, Bertucci F, Borg JP, Camoin L. Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer. Oncotarget 2018;9:33762-77. [PMID: 30333908 DOI: 10.18632/oncotarget.26031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
180 Koneru S, Sato K, Goldberg A, Sanghi V, Montero A, Grimm RA, Rodriguez LL, Griffin BP, Budd GT, Collier PC, Tamarappoo B, Desai MY, Popović ZB. Pertuzumab/Trastuzumab Breast Cancer Therapy Is Associated With Complex Hemodynamic Abnormalities. JACC Cardiovasc Imaging 2018;11:1206-7. [PMID: 30092975 DOI: 10.1016/j.jcmg.2018.05.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
181 Bartsch R, Bergen E, Galid A. Current concepts and future directions in neoadjuvant chemotherapy of breast cancer. Memo 2018;11:199-203. [PMID: 30220926 DOI: 10.1007/s12254-018-0421-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
182 Harbeck N. Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status? Ther Adv Med Oncol 2018;10:1758835918782356. [PMID: 30034548 DOI: 10.1177/1758835918782356] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
183 Basho RK, McArthur HL. Optimizing (neo)adjuvant treatment of HER2-positive breast cancer. Ther Adv Med Oncol 2018;10:1758835918775697. [PMID: 30034547 DOI: 10.1177/1758835918775697] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
184 Suter MB, Pagani O. Should age impact breast cancer management in young women? Fine tuning of treatment guidelines. Ther Adv Med Oncol 2018;10:1758835918776923. [PMID: 29977348 DOI: 10.1177/1758835918776923] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
185 Zekri J, Abdelghany EM, Abed-Alsater F. Pertuzumab: Getting the Balance Right. Oncologist 2018;23:e164-5. [PMID: 29895630 DOI: 10.1634/theoncologist.2017-0316] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
186 Steenbruggen TG, van Ramshorst MS, Kok M, Linn SC, Smorenburg CH, Sonke GS. Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. Drugs 2017;77:1313-36. [PMID: 28616845 DOI: 10.1007/s40265-017-0774-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
187 Debiasi M, Polanczyk CA, Ziegelmann P, Barrios C, Cao H, Dignam JJ, Goss P, Bychkovsky B, Finkelstein DM, Guindalini RS, Filho P, Albuquerque C, Reinert T, de Azambuja E, Olopade O. Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis. Front Oncol 2018;8:156. [PMID: 29872641 DOI: 10.3389/fonc.2018.00156] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
188 Gullo G, Walsh N, Fennelly D, Bose R, Walshe J, Tryfonopoulos D, O'Mahony K, Hammond L, Silva N, McDonnell D, Ballot J, Quinn C, McDermott EW, Evoy D, Prichard R, Geraghty J, Amstrong J, Crown J. Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project. Br J Cancer 2018;119:374-80. [PMID: 29773838 DOI: 10.1038/s41416-018-0114-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
189 Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B; St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017;28:1700-12. [PMID: 28838210 DOI: 10.1093/annonc/mdx308] [Cited by in Crossref: 458] [Cited by in F6Publishing: 429] [Article Influence: 114.5] [Reference Citation Analysis]
190 Hussain N, Said ASA, Khan Z. Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia. Int J Breast Cancer 2018;2018:6106041. [PMID: 29850259 DOI: 10.1155/2018/6106041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
191 Weiss A, Bashour SI, Hess K, Thompson AM, Ibrahim NK. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy. Breast Cancer Res 2018;20:27. [PMID: 29661243 DOI: 10.1186/s13058-018-0945-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
192 Di Cosimo S, Campbell C, Azim HA Jr, Galli G, Bregni G, Curigliano G, Criscitiello C, Izquierdo M, de la Pena L, Fumagalli D, Fein L, Vinholes J, Ng WMJ, Colleoni M, Ferro A, Naume BJ, Patel A, Huober J, Piccart-Gebhart MJ, Baselga J, de Azambuja E. The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO. Eur J Cancer 2018;89:42-8. [PMID: 29227816 DOI: 10.1016/j.ejca.2017.10.036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
193 Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer 2017;3:49. [PMID: 29238749 DOI: 10.1038/s41523-017-0052-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
194 Yu S, Liu Q, Han X, Qin S, Zhao W, Li A, Wu K. Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment. Exp Hematol Oncol 2017;6:31. [PMID: 29209558 DOI: 10.1186/s40164-017-0091-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
195 Connell CM, Doherty GJ. Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open. 2017;2:e000279. [PMID: 29209536 DOI: 10.1136/esmoopen-2017-000279] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 9.0] [Reference Citation Analysis]
196 Wang C, Ye Q, Cao Y, Tan J, Wang F, Jiang J, Cao Y. Downregulation of regulator of G protein signaling 2 expression in breast invasive carcinoma of no special type: Clinicopathological associations and prognostic relevance. Oncol Lett 2018;15:213-20. [PMID: 29391880 DOI: 10.3892/ol.2017.7351] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
197 Florido R, Smith KL, Cuomo KK, Russell SD. Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. J Am Heart Assoc 2017;6:e006915. [PMID: 28939718 DOI: 10.1161/JAHA.117.006915] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
198 Fujii S, Yamashita S, Yamaguchi T, Takahashi M, Hozumi Y, Ushijima T, Mukai H. Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation. Oncotarget 2017;8:19039-48. [PMID: 28186977 DOI: 10.18632/oncotarget.15118] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
199 Boughey JC, Ballman KV, McCall LM, Mittendorf EA, Symmans WF, Julian TB, Byrd D, Hunt KK. Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance). Ann Surg 2017;266:667-76. [PMID: 28657941 DOI: 10.1097/SLA.0000000000002373] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 6.2] [Reference Citation Analysis]
200 Wu D, Si M, Xue HY, Wong HL. Nanomedicine applications in the treatment of breast cancer: current state of the art. Int J Nanomedicine 2017;12:5879-92. [PMID: 28860754 DOI: 10.2147/IJN.S123437] [Cited by in Crossref: 57] [Cited by in F6Publishing: 22] [Article Influence: 11.4] [Reference Citation Analysis]
201 Martin G, Shaughnessy E. Breast Cancer Care in the Elderly Patient. Curr Geri Rep 2017;6:139-48. [DOI: 10.1007/s13670-017-0218-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
202 Wein L, Savas P, Luen SJ, Virassamy B, Salgado R, Loi S. Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. Front Oncol 2017;7:156. [PMID: 28824872 DOI: 10.3389/fonc.2017.00156] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 8.8] [Reference Citation Analysis]
203 Boland MR, McVeigh TP, O'Flaherty N, Gullo G, Keane M, Quinn CM, McDermott EW, Lowery AJ, Kerin MJ, Prichard RS. Impact of receptor phenotype on nodal burden in patients with breast cancer who have undergone neoadjuvant chemotherapy. BJS Open 2017;1:39-45. [PMID: 29951604 DOI: 10.1002/bjs5.6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
204 Nowsheen S, Viscuse PV, O'Sullivan CC, Sandhu NP, Haddad TC, Blaes A, Klemp J, Nhola L, Herrmann J, Ruddy KJ. Incidence, Diagnosis, and Treatment of Cardiac Toxicity from Trastuzumab in Patients with Breast Cancer. Curr Breast Cancer Rep 2017;9:173-82. [PMID: 29225726 DOI: 10.1007/s12609-017-0249-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
205 Kourie HR, El Rassy E, Clatot F, de Azambuja E, Lambertini M. Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib. Onco Targets Ther 2017;10:3363-72. [PMID: 28744140 DOI: 10.2147/OTT.S122397] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
206 von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;377:122-131. [PMID: 28581356 DOI: 10.1056/nejmoa1703643] [Cited by in Crossref: 538] [Cited by in F6Publishing: 244] [Article Influence: 107.6] [Reference Citation Analysis]
207 Gerson JN, Skariah S, Denlinger CS, Astsaturov I. Perspectives of HER2-targeting in gastric and esophageal cancer. Expert Opin Investig Drugs 2017;26:531-40. [PMID: 28387541 DOI: 10.1080/13543784.2017.1315406] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
208 Earl H, Molica S, Rutkowski P. Spotlight on landmark oncology trials: the latest evidence and novel trial designs. BMC Med 2017;15:111. [PMID: 28571584 DOI: 10.1186/s12916-017-0884-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
209 Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C; Herceptin Adjuvant (HERA) Trial Study Team. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389:1195-1205. [PMID: 28215665 DOI: 10.1016/s0140-6736(16)32616-2] [Cited by in Crossref: 370] [Cited by in F6Publishing: 197] [Article Influence: 74.0] [Reference Citation Analysis]
210 Quartino AL, Li H, Jin JY, Wada DR, Benyunes MC, McNally V, Viganò L, Nijem I, Lum BL, Garg A. Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer. Cancer Chemother Pharmacol 2017;79:353-61. [PMID: 28074265 DOI: 10.1007/s00280-016-3218-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
211 Fasching PA, Gaß P, Hein A. Neoadjuvant Treatment of Breast Cancer - Advances and Limitations. Breast Care (Basel) 2016;11:313-4. [PMID: 27920622 DOI: 10.1159/000452463] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]